Degludec insulin
Phase 3Small molecule
Sunshine Lake Pharma Co., Ltd.Degludec insulin is one of 57 small molecule programs targeting Critically Ill Patients. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
113 competitors in Diabetes Mellitus
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Actos
TakedaApproved
Jardiance
Boehringer IngelheimApproved
Onglyza
AstraZenecaApproved
Geodon
PfizerApproved
Tradjenta
Boehringer IngelheimApproved
Januvia
ZZydus Therapeutics Inc.
Approved
Topamax
WWim Janssens
Approved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Retatrutide
Eli LillyPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diabetes Mellitus1 trial
A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus
Enrolling by invitation·—·Phase 4·NCT06925334·170 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Degludec insulin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details